Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

NCT07747740 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

228

Enrollment

OTHER

Sponsor class

Conditions

Non-Muscle-Invasive Bladder Cancer
BCG-Unresponsive Bladder Cancer

Interventions

DRUG: Gemcitabin
DRUG: Docetaxel
DRUG: Mitomicin C

Sponsor

Blokhin's Russian Cancer Research Center